Manufacturer
47 recalls in our database name Zydus Pharmaceuticals (USA) Inc as the manufacturing or recalling firm.
The manufacturer string comes from the agency’s own source notice — for FDA recalls, the “recalling firm” field; for NHTSA recalls, the vehicle manufacturer; for CPSC recalls, the firm-of-record on the joint press release. A single corporate family can appear under multiple manufacturer strings as agency notices aren’t standardized on a canonical name. If you don’t see recalls you expect, try a parent-company search or a broader full-text search.
Severity scores below are computed from the agency’s classification and the recall text, never from manufacturer behaviour or history. Many manufacturers issue routine corrective actions (software updates, labelling corrections) that are correctly scored low — having recalls on this list isn’t inherently a quality signal.
Zydus Pharmaceuticals is recalling Erythromycin Tablets, 250 mg, nationwide because certain lots contain N-Nitroso-Desmethyl-Erythromycin above the recommended acceptable intake limit due to CGMP deviations.
Zydus Pharmaceuticals is recalling erythromycin 500 mg tablets nationwide due to the presence of N-Nitroso-Desmethyl-Erythromycin above the recommended acceptable intake limit, resulting from manufacturing deviations.
Pending LLM rewrite. Source: FDA_DRUG D-0400-2026.
Pending LLM rewrite. Source: FDA_DRUG D-0295-2026.
Pending LLM rewrite. Source: FDA_DRUG D-0247-2026.
Pending LLM rewrite. Source: FDA_DRUG D-0159-2026.
Pending LLM rewrite. Source: FDA_DRUG D-0153-2026.
Pending LLM rewrite. Source: FDA_DRUG D-0154-2026.
Pending LLM rewrite. Source: FDA_DRUG D-0152-2026.
Pending LLM rewrite. Source: FDA_DRUG D-0001-2026.
Pending LLM rewrite. Source: FDA_DRUG D-0002-2026.
Pending LLM rewrite. Source: FDA_DRUG D-0656-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0657-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0637-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0633-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0639-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0635-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0623-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0634-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0632-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0636-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0631-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0630-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0638-2025.
Zydus Pharmaceuticals is recalling Icosapent Ethyl Capsules due to burnt or melted capsules caused by oxidation from leakage of capsule contents. The recall affects 11,616 bottles distributed in Illinois, Pennsylvania, and Mississippi.